- Home
- INCY vs APTV Comparison
INCY vs APTV Comparison
Compare INCY & APTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- APTV
- Stock Information
- Founded
- INCY 1991
- APTV 2011
- Country
- INCY United States
- APTV Switzerland
- Employees
- INCY N/A
- APTV N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- APTV Auto Parts:O.E.M.
- Sector
- INCY Health Care
- APTV Consumer Discretionary
- Exchange
- INCY Nasdaq
- APTV Nasdaq
- Market Cap
- INCY 13.0B
- APTV 15.4B
- IPO Year
- INCY 1993
- APTV 1999
- Fundamental
- Price
- INCY $70.20
- APTV $70.92
- Analyst Decision
- INCY Hold
- APTV Buy
- Analyst Count
- INCY 20
- APTV 19
- Target Price
- INCY $72.75
- APTV $79.27
- AVG Volume (30 Days)
- INCY 1.5M
- APTV 2.1M
- Earning Date
- INCY 07-29-2025
- APTV 07-31-2025
- Dividend Yield
- INCY N/A
- APTV N/A
- EPS Growth
- INCY N/A
- APTV N/A
- EPS
- INCY 0.10
- APTV 6.35
- Revenue
- INCY $4,413,226,000.00
- APTV $19,637,000,000.00
- Revenue This Year
- INCY $13.48
- APTV $1.92
- Revenue Next Year
- INCY $10.37
- APTV $4.70
- P/E Ratio
- INCY $723.63
- APTV $11.18
- Revenue Growth
- INCY 17.13
- APTV N/A
- 52 Week Low
- INCY $53.56
- APTV $47.19
- 52 Week High
- INCY $83.95
- APTV $80.95
- Technical
- Relative Strength Index (RSI)
- INCY 55.91
- APTV 55.10
- Support Level
- INCY $67.17
- APTV $69.75
- Resistance Level
- INCY $71.29
- APTV $72.43
- Average True Range (ATR)
- INCY 1.51
- APTV 1.61
- MACD
- INCY 0.06
- APTV -0.10
- Stochastic Oscillator
- INCY 74.23
- APTV 65.58
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About APTV Aptiv PLC
Aptiv PLC signal and power solutions segment supplies components and systems that make up a vehicle's electrical system, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The operating segments are grouped on the basis of similar product, market and operating factors: Signal and Power Solutions, which includes complete electrical architecture and component products. advanced Safety and User Experience, which includes vehicle technology and services in advanced safety, user experience, and smart vehicle computing and software, as well as cloud-native software platforms, autonomous driving technologies, and DevOps tools. Eliminations and Other.